-
Review
January 22, 2025
- Unveiling the intratumor microbiome in liver cancer: Current insights and prospective applications
- Xindi Ke, Shangze Jiang, Qiaoxin Wei, et al.
- Clin Mol Hepatol. 2025;31(3):685-705.
Articles in E-pub version are posted online ahead of regular printed publication.
- Correspondence
- Response to Editorial on Ciociola et al., "Downregulation of the MARC1 p.A165 Risk Allele Reduces Hepatocyte Lipid Content by Increasing Beta-Oxidation"
- Ester Ciociola, Tanmoy Dutta, Rosellina M. Mancina, Stefano Romeo
- Received July 11, 2025 Accepted July 11, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0765 [Accepted]
-
View: 4 Download: 1
- Correspondence to “Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation”
- Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
- Received July 10, 2025 Accepted July 11, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0760 [Accepted]
-
View: 6 Download: 2
- Editorial
- Editorial on “Factors associated with hepatitis B mother-to-child transmission in a national prevention program”: Redefining MTCT prevention strategies toward HBV elimination
- Eunho Choi, Ji Hoon Kim, Young-Sun Lee
- Received July 8, 2025 Accepted July 11, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0747 [Accepted]
-
View: 6 Download: 0
- Clinical implications of residual changes following HCV clearance
- So-Young Kim, Eui-Cheol Shin
- Received July 3, 2025 Accepted July 11, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0728 [Accepted]
-
View: 6 Download: 2
- Letter to the Editor
- Letter to the editor on” Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial. ”
- Bitao Jiang, Song Zhang, Lingling Bao
- Received June 28, 2025 Accepted July 10, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0699 [Accepted]
-
View: 15 Download: 1
- Reconsidering the Role of Plasma pgRNA in NUC-treated CHB: Stratified Biomarker Interpretation and the Limits of Current Assays
- Xu Han, Jun Sun, Yinyan Li
- Received June 16, 2025 Accepted July 6, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0642 [Accepted]
-
View: 76 Download: 9
- Editorial
- Opportunities and challenges in controlling metabolic dysfunction-associated steatotic liver disease (MASLD): Editorial on “Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation”
- Jian Xu, Gang Shi, Tao Sheng, Jingdong Li
- Received June 30, 2025 Accepted July 3, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0708 [Accepted]
-
View: 139 Download: 19
- Correspondence
- Correspondence to editorial on “GLP-1RA may open a new era for MASLD treatment”
- Xianhua Mao, Mindie H Nguyen
- Received June 29, 2025 Accepted July 2, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0705 [Accepted]
-
View: 92 Download: 7
- Reply: Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias?
- Xianhua Mao, Mindie H Nguyen
- Received June 29, 2025 Accepted July 3, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0704 [Accepted]
-
View: 64 Download: 4
- Editorial
- The other face of GWAS: Editorial on “Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD”
- Hyungtai Sim, Murim Choi
- Received June 22, 2025 Accepted July 2, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0677 [Accepted]
-
View: 78 Download: 6
- Original Article
- Human cytomegalovirus reactivation in cirrhosis patients with acute decompensation
- Changze Hong, Zuxiong Huang, Yingli He, Rongqi Wang, Jiaying Lin, Yushan Liu, Baicheng Liu, Xiaoqin Lan, Qinjun He, Wenfan Luo, Qintao Lai, Ling Zhou, Tingting Qi, Yali Ji, Miaoxia Liu, Qiaoping Wu, Yichen Yao, Weihao Liang, Xianbo Wang, Guohong Deng, Yanhang Gao, Yan Huang, Feng Liu, Xiaobo Lu, Zhongji Meng, Yuemin Nan, Hai Li, Beiling Li, Rajiv Jalan, Jinjun Chen
- Received March 25, 2025 Accepted July 1, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0332 [Accepted]
-
View: 261 Download: 23
- Editorial
- Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunctionassociated steatotic liver disease”: Rethinking first-line screening in MASLD: beyond the limitations of Fibrosis-4 index
- Han Ah Lee, Young Youn Cho, Hyung Joon Kim
- Received June 23, 2025 Accepted June 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0678 [Accepted]
-
View: 146 Download: 16
- Letter to the Editor
- Letter"Novel Genetic Modulators of MASLD Identified Through Genome-Wide Interaction with BMI"
- Sheng Zheng
- Received June 18, 2025 Accepted June 26, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0656 [Accepted]
-
View: 143 Download: 10
- Correspondence
- Correspondence to letter to the editor on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
- Hye Won Lee, Seung Up Kim
- Received June 17, 2025 Accepted June 20, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0644 [Accepted]
-
View: 142 Download: 9
- Editorial
- GLP-1RA may open a new era for MASLD treatment
- Ye Feng, Chengfu Xu
- Received June 12, 2025 Accepted June 19, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0628 [Accepted]
-
View: 225 Download: 32
- Letter to the Editor
- Critical Flaws in the Molecular Classification of HCC Based on Metabolic Zonation
- Yongzhi Xie, Xiangyu Zhu, Qi Liang
- Received June 9, 2025 Accepted June 20, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0610 [Accepted]
-
View: 153 Download: 18
- Review
- Update in the Treatment of Cirrhotic Patients with Portal Vein Thrombosis
- Jialin Wu, Xinyi Deng, Junyang Luo, Zaibo Jiang, Fuda Xie, Bonan Chen, Hoi Wing Leung, Ge Zhang, Ka Fai To, Wei Kang
- Received April 12, 2025 Accepted June 19, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0411 [Accepted]
-
View: 426 Download: 107
- Original Article
- Factors associated with hepatitis B mother-to-child transmission in a national prevention program
- Moran Ki, Byung-Woo Kim, Dahye Baik, Jong-Hyun Kim
- Received February 24, 2025 Accepted June 20, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0214 [Accepted]
-
View: 272 Download: 48
- Reply to Correspondence
- Correspondence on “Reply to "Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers"”
- Dibin Liu
- Received June 8, 2025 Accepted June 13, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0604 [Accepted]
-
View: 177 Download: 20
- Correspondence
- Reply to the letter to the editor on “Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
- Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang
- Received June 5, 2025 Accepted June 13, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0594 [Accepted]
-
View: 237 Download: 8
- Reply to the letter：Advancing the Baveno VI-SSM Model for Clinical Utility in HBV-Related Cirrhosis
- Haiyu Wang, Jinjun Chen
- Received June 9, 2025 Accepted June 10, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0611 [Accepted]
-
View: 165 Download: 2
- Original Article
- Non-contrast MRI for Detection of Late Recurrent Hepatocellular Carcinoma After Curative Treatment: A Prospective Multicenter Comparison to Contrast-enhanced CT
- Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
- Received March 4, 2025 Accepted June 10, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0258 [Accepted]
-
View: 440 Download: 59
- Letter to the Editor
- Letter “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
- Jun Sun, Xu Han, Yinyan Li
- Received June 2, 2025 Accepted June 4, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0586 [Accepted]
-
View: 229 Download: 19
- Re: “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
- Bitao Jiang, Lingling Bao
- Received June 1, 2025 Accepted June 4, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0584 [Accepted]
-
View: 207 Download: 23
- Early Cancer Risk Reduction After GLP-1RA Use: Signal or Bias?”
- Shio-Shin Jean, Chih-Cheng Lai
- Received May 31, 2025 Accepted June 4, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0583 [Accepted]
-
View: 186 Download: 21
- Review
- Prospects of Mendelian Randomization in Hepatology: A Comprehensive Literature Review with Practice Guidance Mendelian randomization and hepatology
- Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke
- Received May 16, 2025 Accepted June 3, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0541 [Accepted]
-
View: 810 Download: 91
- Letter to the Editor
- Letter "Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease"
- Chunyan Wang, Jun Sun, Yinyan Li
- Received May 16, 2025 Accepted June 5, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0539 [Accepted]
-
View: 224 Download: 13
- Reply to Correspondence
- Reply to correspondence on “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”
- Heejoon Jang, Won Kim
- Received May 14, 2025 Accepted June 4, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0533 [Accepted]
-
View: 414 Download: 1
- Reply to correspondence on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
- Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
- Received May 26, 2025 Accepted May 30, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0564 [Accepted]
-
View: 310 Download: 12
- Reply to correspondence on “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
- Sung-Eun Kim
- Received May 15, 2025 Accepted May 30, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0536 [Accepted]
-
View: 194 Download: 14
- Letter to the Editor
- Letter “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
- Bo Zheng, Lizhou Wang
- Received May 11, 2025 Accepted May 31, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0521 [Accepted]
-
View: 185 Download: 18
- Original Article
- Distinct Inflammatory Imprint in Non-Cirrhotic and Cirrhotic Patients Before and After Direct-Acting Antiviral Therapy
- Moana Witte, Carlos Oltmanns, Jan Tauwaldt, Hagen Schmaus, Jasmin Mischke, Gordon Grabert, Mara Bretthauer, Lennart M. Roesner, Thomas Werfel, Katja Deterding, Benjamin Maasoumy, Heiner Wedemeyer, Tim Kacprowski, Anke R.M. Kraft, Markus Cornberg
- Received March 20, 2025 Accepted June 2, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0292 [Accepted]
-
View: 501 Download: 46
- Reply to Correspondence
- Reply to correspondence on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression
- Many Sze Man Chan, Terence Kin Wah Lee
- Received May 14, 2025 Accepted May 30, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0530 [Accepted]
-
View: 244 Download: 6
- Original Article
- Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD
- Oveis Jamialahmadi, Endrina Mujica, Lowri Morris, Rosellina Margherita Mancina, Ester Ciociola, Sami F. Qadri, Samantha Maurotti, Francesco Malvestiti, Ruifang Li-Gao, Luisa Ronzoni, Federica Tavaglione, Hannah Maude, Amin Allalou, Anastasia Emmanouilidou, Umberto Vespasiani-Gentilucci, Frits Richard Rosendaal, Hannele Yki-Järvinen, Inês Cebola, Luca Valenti, Marcel den Hoed, Stefano Romeo
- Received February 26, 2025 Accepted May 29, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0159 [Accepted]
-
View: 813 Download: 96
- Letter to the Editor
- Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
- Dibin Liu
- Received May 15, 2025 Accepted May 23, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0537 [Accepted]
-
View: 158 Download: 15
- Correspondence
- Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
- Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
- Received May 13, 2025 Accepted May 14, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0527 [Accepted]
-
View: 365 Download: 7
- Correspondence: Response to Editorial on “Uncovering the MET-TRIB3-FOXO1 axis: A Novel Target in MET-driven Hepatocellular Carcinoma”
- Tiantian Wang, Wenjie Huang, Limin Xia
- Received May 11, 2025 Accepted May 14, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0523 [Accepted]
-
View: 379 Download: 12
- Editorial
- Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications
- Sung-Eun Kim
- Received May 9, 2025 Accepted May 13, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0516 [Accepted]
-
View: 233 Download: 11
- Uncovering the MET-TRIB3-FOXO1 axis: A Novel Target in MET-driven Hepatocellular Carcinoma
- Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
- Received May 9, 2025 Accepted May 13, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0515 [Accepted]
-
View: 493 Download: 44
- Correspondence
- Correspondence: Response to Editorial on “Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression”
- Tiantian Wang, Wenjie Huang, Limin Xia
- Received May 6, 2025 Accepted May 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0507 [Accepted]
-
View: 336 Download: 16
- Reply to Correspondence
- Advancing Metabolic Risk Profiling in Chronic Hepatitis B
- Shang-Chin Huang, Jia-Horng Kao
- Received May 4, 2025 Accepted May 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0500 [Accepted]
-
View: 237 Download: 11
- Reply to correspondence on “A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on ‘Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway’”
- Eun Ji Jang, Pil Soo Sung
- Received May 3, 2025 Accepted May 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0498 [Accepted]
-
View: 216 Download: 9
- Correspondence
- Correspondence to editorial “Metabolic health in antiviral era of chronic hepatitis B”
- Rui Huang, Mindie H. Nguyen
- Received April 29, 2025 Accepted May 4, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0479 [Accepted]
-
View: 284 Download: 3
- Correspondence to editorial “Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B”
- Rui Huang, Mindie H. Nguyen
- Received April 29, 2025 Accepted May 3, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0478 [Accepted]
-
View: 253 Download: 3
- Correspondence to letter to the editor on “Risk Stratification of Metabolic Dysfunction-Associated Steatotic Liver Disease: The KASL Pathway
- Hye Won Lee, Seung Up Kim
- Received April 29, 2025 Accepted May 3, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0477 [Accepted]
-
View: 256 Download: 4
- Letter to the Editor
- Molecular Stratification of Hepatocellular Carcinoma by Metabolic-Signaling Pathways Guides Precision Immunotherapy and TACE Therapy
- Binghua Li, Yanchao Xu, Yican Zhu, Yukun Zhang, Zijie Wu, Tianci Luo, Laizhu Zhang, Weiwei Hu, Decai Yu
- Received March 27, 2025 Accepted April 29, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0344 [Accepted]
-
View: 453 Download: 63 Crossref: 1
- Editorial
- Unveiling TRIB3: A New Mediator in MET-Driven Hepatocellular Carcinoma Progression
- Many Sze Man CHAN, Terence Kin Wah LEE
- Received April 23, 2025 Accepted April 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0452 [Accepted]
-
View: 378 Download: 30
- Correspondence
- Correspondence to editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway.”
- Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
- Received April 18, 2025 Accepted April 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0435 [Accepted]
-
View: 289 Download: 14
- Editorial
- Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B
- Heejoon Jang, Won Kim
- Received April 16, 2025 Accepted April 25, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0430 [Accepted]
-
View: 603 Download: 18
- RISK STRATIFICATION OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: THE KASL PATHWAY
- May Xuan GOH, Xin En GOH, Jarell Jie-Rae TAN, Vincent L CHEN, Yu Jun WONG
- Received April 14, 2025 Accepted April 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0420 [Accepted]
-
View: 272 Download: 19
- Reply to Correspondence
- GULP1: New Hope for Hepatocellular Carcinoma: Reply to Correspondence on “GULP1 as a Novel Biomarker in HCC”
- Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
- Received April 14, 2025 Accepted April 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0415 [Accepted]
-
View: 304 Download: 16
- Correspondence
- Correspondence to editorial “Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma”
- Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu
- Received April 11, 2025 Accepted April 24, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0402 [Accepted]
-
View: 1271 Download: 24
- Letter to the Editor
- Letter “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”
- Yuqian Liu, Ruiyun Guo, Jun Ma
- Received April 6, 2025 Accepted April 21, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0377 [Accepted]
-
View: 348 Download: 40
- Editorial
- A Novel Link Between Tumor Cell Metabolism and Patient Prognosis: Editorial on “Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway”
- Eun Ji Jang, Pil Soo Sung
- Received April 9, 2025 Accepted April 14, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0395 [Accepted]
-
View: 303 Download: 13
- Reply to Correspondence
- Reply to authors’ reply: “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
- Mathias Jachs, Mattias Mandorfer
- Received April 9, 2025 Accepted April 14, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0391 [Accepted]
-
View: 339 Download: 11
- Correspondence
- Correspondence to Editorial on “Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial”
- Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
- Received April 7, 2025 Accepted April 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0379 [Accepted]
-
View: 296 Download: 16
- Editorial
- Metabolic Health in Antiviral Era of Chronic Hepatitis B
- Shang-Chin Huang, Jia-Horng Kao
- Received April 3, 2025 Accepted April 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0369 [Accepted]
-
View: 367 Download: 23
- Viral manipulation of host cell glutamine metabolism and glutamine rewiring in hepatic diseases: Editorial on “GDH1-dependent α-ketoglutarate promotes HBV transcription by modulating histone methylations on the cccDNA minichromosome”
- Mehrangiz Dezhbord, Kyun-Hwan Kim
- Received April 2, 2025 Accepted April 8, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0366 [Accepted]
-
View: 395 Download: 50
- Correspondence
- Revisiting unmet needs in clinical research on direct-acting antiviral therapy for HCC patients
- Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
- Received April 2, 2025 Accepted April 2, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0362 [Accepted]
-
View: 519 Download: 15
- Correspondence: Response to Editorial on “GULP1, a Multifaceted Biomarker and Therapeutic Target in HCC”
- Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun
- Received March 28, 2025 Accepted April 2, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0350 [Accepted]
-
View: 351 Download: 11
- Editorial
- Targeting CD36 to reinvigorate CD8+ T Cells in early-stage hepatocellular carcinoma
- Valerie Chew
- Received March 25, 2025 Accepted March 28, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0334 [Accepted]
-
View: 547 Download: 42
- Correspondence
- Correspondence to editorial 3 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
- Haiyu Wang, Jinjun Chen
- Received March 23, 2025 Accepted March 28, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0328 [Accepted]
-
View: 368 Download: 7
- Correspondence to editorial 2 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
- Haiyu Wang, Jinjun Chen
- Received March 23, 2025 Accepted March 28, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0327 [Accepted]
-
View: 391 Download: 6
- Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
- Haiyu Wang, Jinjun Chen
- Received March 23, 2025 Accepted March 28, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0326 [Accepted]
-
View: 383 Download: 13
- Editorial
- GULP1, A Multifaceted Diagnostic Biomarker and Potential Therapeutic Target in Hepatocellular Carcinoma: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
- Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
- Received March 18, 2025 Accepted March 21, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0315 [Accepted]
-
View: 475 Download: 32
- Besifovir: a viable option for long-term disease control in chronic hepatitis B
- Wai-Kay Seto
- Received March 15, 2025 Accepted March 20, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0305 [Accepted]
-
View: 309 Download: 18
- Refining Portal Hypertension Assessment: The Clinical Significance of Spleen Stiffness Measurement in the Baveno VII Era
- Do Seon Song
- Received March 13, 2025 Accepted March 20, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0296 [Accepted]
-
View: 361 Download: 34
- Letter to the Editor
- Letter “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
- Qiong Wang, Zhongqing Qian, Xiaodi Yang, Deyan Chen, Xiaojing Wang, Fuliang Chen
- Received March 13, 2025 Accepted March 19, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0291 [Accepted]
-
View: 376 Download: 22
- Correspondence
- Correspondence: Response to the Letter Regarding "GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma"
- Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
- Received March 12, 2025 Accepted March 15, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0287 [Accepted]
-
View: 512 Download: 27
- Editorial
- Unveiling GULP1 as a Hepatocyte-Specific Role for Recurrence: Editorial on “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
- Pengde Lu, Ning Wang
- Received March 11, 2025 Accepted March 15, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0282 [Accepted]
-
View: 485 Download: 25
- A non-invasive risk stratification tool for hepatitis B-related liver cirrhosis: the Baveno VI-SSM combined model.
- Ruiling He, Bingtian Dong, Xiaolong Qi
- Received March 11, 2025 Accepted March 15, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0281 [Accepted]
-
View: 534 Download: 37
- Predicting decompensation risk in compensated HBV cirrhosis: Eternal sunshine for a spotless mind?
- Mathias Jachs, Mattias Mandorfer
- Received March 11, 2025 Accepted March 15, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0280 [Accepted]
-
View: 439 Download: 28
- The Evolution of Non-Invasive Strategies in Cirrhosis Management—From Screening to Precision Monitoring：Editorial on ‘FIB-4plus Score: A novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): An international multicenter study’
- Haiyu Wang, Jinjun Chen
- Received March 9, 2025 Accepted March 15, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0274 [Accepted]
-
View: 467 Download: 23
- Letter to the Editor
- Critical Considerations in Evaluating the Therapeutic Potential of HK-660S for Primary Sclerosing Cholangitis
- He Yizi, He Haifeng, Liang Qi, Xie Yongzhi
- Received March 1, 2025 Accepted March 13, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0239 [Accepted]
-
View: 383 Download: 32
- Reply to Correspondence
- SHOULD DIRECT-ACTING ANTIVIRAL BE CONSIDERED FOR ALL PATIENTS WITH HCV-RELATED HEPATOCELLULAR CARCINOMA?
- Yan Ling ONG, Apichat KAEWDECH, Yu Jun WONG
- Received March 5, 2025 Accepted March 10, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0257 [Accepted]
-
View: 396 Download: 13
- Editorial
- Modulation of PRL-1 in Placental MSCs: A Novel Therapeutic Strategy for Hepatic Fibrosis: Editorial on “Modulation of PRL-1 within placental MSCs instigates the transition between EMT and MET subsequent to hepatic fibrosis”
- Lihai Jiang, Wenjie Zheng
- Received March 5, 2025 Accepted March 9, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0264 [Accepted]
-
View: 392 Download: 18
- Regulation of Hepatitis B Virus cccDNA by Metabolic Pathways
- Hyeong-Jin Cho, Sung-Gyoo Park
- Received March 4, 2025 Accepted March 9, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0255 [Accepted]
-
View: 584 Download: 57 Crossref: 1
- Letter to the Editor
- Letter “GULP1 as a Novel Diagnostic and Predictive Biomarker in Hepatocellular Carcinoma”
- Juan Yang, Xinyi Li, Sheng Zheng
- Received February 24, 2025 Accepted March 5, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0216 [Accepted]
-
View: 520 Download: 54
- Letter to the Editor on “Current Burden of Steatotic Liver Disease and Fibrosis among Adults in the United States, 2017-2023”
- Sisi Yang, Zhenxuan Ma
- Received February 11, 2025 Accepted March 6, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0153 [Accepted]
-
View: 437 Download: 23
- Correspondence
- Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage
- Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming- Lung Yu
- Received February 28, 2025 Accepted March 1, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0235 [Accepted]
-
View: 640 Download: 23
- HCC predictors in routine practice for patients with chronic liver diseases
- Tung-Hung Su, Jia-Horng Kao
- Received February 18, 2025 Accepted February 22, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0187 [Accepted]
-
View: 361 Download: 11
- Editorial
- Direct-acting antiviral attained sustained virological response improve overall survival in patients with HCV-related hepatocellular carcinoma
- Yan Ling Ong, Apichat Kaewdech, Daniel Q Huang, Yu Jun Wong
- Received February 14, 2025 Accepted February 21, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0174 [Accepted]
-
View: 581 Download: 32
- Can SAFE score be utilized as a universal hepatocellular carcinoma prediction score? Editorial on “High SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease”
- Michael Kwan-Lung Ko, Loey Lung-Yi Mak
- Received February 3, 2025 Accepted February 7, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0118 [Accepted]
-
View: 419 Download: 23
- Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease
- Ho Soo Chun, Minjong Lee
- Received February 2, 2025 Accepted February 7, 2025
-
DOI: https://doi.org/10.3350/cmh.2025.0116 [Accepted]
-
View: 544 Download: 21
- Original Article
- Plasma lipidomics and fungal peptide-based community analysis identifies distinct signatures for early mortality in acute liver failure
- Neha Sharma, Sushmita Pandey, Gaurav Tripathi, Manisha Yadav, Nupur Sharma, Babu Mathew, Abhishak Gupta, Vasundhra Bindal, Sadam H. Bhat, Yash magar, Rimsha Saif, Sanju Yadav, Amritpal Kaur, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras
- Received July 12, 2024 Accepted December 10, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0554 [Accepted]
-
View: 5589 Download: 145
